CClinicalTrials.gg
CompletedNCT00626379CHASUpdated May 3, 2023

Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])

An observational study in Coronary Disease and Cardiovascular Diseases, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 65 Years to 84 Years. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Northwestern University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,395
Ages
65 Years to 84 Years
Sex
All
01

Study summary

Heart disease is the leading cause of death in the United States and is responsible for 30% of all deaths in the United States. This study will examine how risk factors for heart disease in young and middle aged people affect people's health as they grow older.

Read the detailed description

Heart disease, including coronary heart disease (CHD) and cardiovascular disease (CVD), is a serious health problem in the United States. It is the leading cause of death in this country, and each year almost 700,000 people die from the disease. Risk factors for heart disease include high blood pressure, high cholesterol levels, tobacco use, diabetes, and history of a prior heart attack. It has been shown that young and middle aged adults with few risk factors experience a lower incidence of heart disease, lower Medicare costs, and longer lives than those with more risk factors. However, it is not known how having a low risk for heart disease at a young age affects health-related outcomes in older age. It may be possible that a low risk for developing heart disease in younger years results in healthier aging than does a higher risk. This study will examine former participants of the Chicago Heart Association (CHA) study who are now 65 to 84 years old. The purpose of this study is to determine how risk factors for heart disease in young adulthood and middle age are related to healthy aging.

This study will enroll 1500 people who participated in the CHA study from 1967 to 1973 and who are still living in the Greater Chicagoland area. Six hundred former participants who had a low risk of developing heart disease and 900 former participants who had a high risk of developing heart disease will be enrolled. Participants will attend one study visit that will include medical history interviews and questionnaires, a physical examination, blood pressure measurements, blood and urine collection, and an electrocardiogram (ECG) to measure the electrical activity of the heart. Blood samples will be collected and stored for future genetic testing. Participants will undergo physical functioning performance tests on balance, leg strength and coordination, grip strength, and endurance. They will also undergo a computed tomography chest scan to measure the amount of calcium in the arteries of the heart and ultrasound scans of the arteries in the neck to measure artery size and function.

02

Conditions studied

  • Coronary Disease
  • Cardiovascular Diseases

Keywords

  • Coronary Heart Disease
  • Subclinical Atherosclerosis
  • CVD-Related Markers of Inflammation
  • Mortality
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 1,395 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,396 studies on the registry; 199 are open to participants now.

Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Original participants in the Chicago Heart Association (CHA) Detection in Industry study (1967 to 1973) who still reside in the Greater Chicagoland area.

Inclusion criteria

  • Participated in the CHA study
  • Lives in the Greater Chicagoland area

Exclusion criteria

Exclusion Criteria:

  • Severely ill, disabled, or cognitively impaired
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,395 participants (actual)
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Subclinical atherosclerosis, CVD-related markers of inflammation, and levels of physical performance

    Time frame: Measured during participant's one (baseline) study visit

07

Study locations

1 site
  • Preventive Medicine Research Clinic
    Chicago, Illinois 60611, United States
08

References and documents

Individual participant data

Plan to share: No — No plan to share.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00626379
Lead sponsor
Northwestern University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sponsor
First posted
Feb 29, 2008
Start date
Nov 2007
Primary completion
Aug 2010
Completion
Dec 2010
Last update
May 3, 2023

Study contacts

Martha L. Daviglus, MD, PhD
principal investigator · Northwestern University Feinberg School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion